Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the
Board of Directors has tasked the company management with reviewing the
possibility of dividing the company’s operations into two independent companies
and achieving a separate listing for the commercial pharmaceutical portfolio.
The Board believes that a division of Medivir’s operations into a dedicated
research and development company and a commercial pharmaceutical company could
be advantageous for the company’s shareholders. The objective is to highlight
the value of both the commercial operations and the pharmaceutical projects that
make up the R&D portfolio. In addition, the split would enable the existing
operations to be conducted by two clearly focused, specialised companies where
both companies’ potential can be maximised in line with their different
prerequisites and preconditions. The Board has, therefore, tasked the management
with investigating these opportunities in further detail.
Carnegie Investment Bank and the law firm Vinge have been engaged as advisors
for the process.
For further information, please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 8.30 CET on 15 June 2016.
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.